Navigation Links
Combination vaccines okay for infants, study shows
Date:10/3/2007

A University of Rochester study brings relief to new parents who, while navigating a jam-packed childhood vaccine schedule, can expect to soothe their newborn through as many as 15 pokes by his or her six-month checkup.

The study, recently published in The Journal of Pediatrics, shows that no efficacy or safety is compromised when clinicians administer a new combination vaccine that streamlines the process in effect, tripling up three of the recommended shots to reduce the poke total from five to three, at each of three bimonthly, well-child checkups.

Only more immunizations will enter the schedule, said Michael Pichichero, M.D., professor of Microbiology/Immunology, Pediatrics and Medicine at the University of Rochester and the studys lead author. Coupling or tripling of these vaccines is increasingly important, as this streamlining helps to promote parent compliance, timely vaccination and fewer administration errors.

The study overturns findings (and fears) from a previous study that suggested problems when two specific vaccines were given at the same time Pediarix, a combination of vaccines that guard against diphtheria, tetanus, whooping cough, hepatitis B and poliovirus, and Prevnar, which protects against 76 strains of Streptococcus pneumonia. The earlier studies found that when the vaccines were co-administered, a suboptimal immune response was produced against whooping cough, and more uncomfortable reactions, such as swelling at the injection site, could be expected.

Both Pediarix and Prevnar are recommended for administration at 2-, 4- and 6-month checkups; Prevnar was approved in 2000, shortly before the licensure of Pediarix.

This newest study unseated both early reservations, showing that the combination vaccine was in fact just as safe and as immunogenic as separate shots, even in the midst of other vaccines in the schedule, Pichichero said.

Study Details

A total of 575 h
'/>"/>

Contact: Becky Jones
rebecca_jones@urmc.rochester.edu
585-275-8490
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Smoking and Breast Cancer - A Deadly Combination
3. The bad combination
4. Drug Combinations May Boost Stroke Risk
5. Combination therapy to treat breast cancer
6. Combination regime may work against prostate cancer
7. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
8. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
9. Combination Therapy Effective In Improving Lung Cancer Survival
10. Combination Therapy Found To Improves Stroke Recovery
11. Combination Therapy Found To Be More Effective In Treating Brain Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...Mass., Nov. 27 GSI Group...ier of precision technology products and semicondu...ng of the Company,s shareholders has been schedule...on of the meeting will be announced in due course....requisition notice from Stephen Bershad, a holder ...
(Date:11/27/2009)...CO, Nov. 27 The Gymboree... Lambert, CFO/COO, will present at the NASDAQ OMX ...ay Fair Hotel in London, England, on Wednesday, De... to a live broadcast of The Gymboree Corporation,s...www.gymboree.com, click on "Our Company" at the bo...
(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...
(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...
(Date:11/26/2009)...Nov. 27 With cold and flu season u...od practices to control the spread of infections a...ot only to keep ourselves healthy, but to avoid tr...erty, RN, MS, CIC (certified in infection-control)...ational health at Hospital for Special Surgery (HS...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...riods of blocked blood flow may be better conditio...cording to new research from the University of Cin... UC surgeon-scientist Karyn Butler, MD, found that...yknown as JAK-STATthat protects the heart muscle. ...
...,CVD) today announced that it will present at the ...ary 7 at 7:30 pm ET. Investors may access a,live w...com . In order to register,and download any necess...ive drug development services companies,with reven...
...he gym , , SATURDAY, Jan. 5 (HealthDay New...esolution list, and you don,t even need a gym memb... the correct home equipment, being creative and bo... is to lose weight, but it should not necessarily ...
....,Calvin B. Johnson today invited all Pennsylvania... exhibit at the Farm Show for free health,screenin... information., "Our Body Shop is a fun place for ...n staying fit, preventing,injuries, and detecting ...
...ional group,purchasing organization for the health...o Nonin Medical, Inc. Each year, Amerinet recogniz...nd services to health care,providers across the na...g to millions of people worldwide., "The Niche Su...
...cientists say , , FRIDAY, Jan. 4 (HealthDa...arkinson,s disease may be triggered by a harmful m...w research reveals. , The modification in question...earchers say. , The change short-circuits a proces...
Other Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:Fitness Begins at Home 2Health News:Nonin Medical is Honored With Niche Supplier Award from Amerinet 2Health News:Research Gets Closer to Origin of Parkinson's Disease 2Health News:Research Gets Closer to Origin of Parkinson's Disease 3
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Mammography Equipment - A...ortlinker.com/p0164330/Mammography-Equipment---A-G...nce of breast cancer in industrialized as well as ...ng growth in the mammography market. Globally, esc...
(Date:11/25/2009)..., N.C., Nov. 25 Cempra Pharmaceuti...es, president and chief executive officer, will pr... Conference at 8:50 a.m. EST, December 1, 2009, at...Fernandes will provide an overview of the company,... treatment of drug-resistant pathogens including M...
(Date:11/25/2009)...alif., Nov. 25 ChemoCentryx, Inc... from the Company,s PROTECT-1 (the Prospective Ran... Trial) of Traficet-EN(TM) (CCX282-B) in patients ...ed clinical efficacy with a favorable safety and t...nce of clinical efficacy in the reduction of disea...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Long Term Care Consumer Voices Strengthened 58768 1Long Term Care Consumer Voices Strengthened 58768 2Yongye International Announces 2010 2012 Strategic Plan 14335 1Yongye International Announces 2010 2012 Strategic Plan 14335 2Yongye International Announces 2010 2012 Strategic Plan 14335 3Yongye International Announces 2010 2012 Strategic Plan 14335 4Yongye International Announces 2010 2012 Strategic Plan 14335 5Face Masks Offer Protection Against Spreading H1N1 5187 1Face Masks Offer Protection Against Spreading H1N1 5187 2
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) an... milestones,achieved in 2008 and preview objective...Briefing to be held in New York City today. , Da...poration,s Research,Biotech Business Unit will dis...o companies, collaboration to commercialize zinc f...
...f., Dec. 3 Isis Pharmaceuticals,Inc. (Nasdaq: I...ls, Inc.,provided positive survival results from a...ombination with docetaxel and prednisone ("the OGX...one ("the control arm") for first-line,treatment o...The current 10.6,month median overall survival adv...
Other Medicine Technology:Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4
MIS Distal Femoral Alignment/Saw Guide and Intramedullary Rod
Ascent Anterior Referencing Femoral Instrument Case
Ascent Knee System Case # 2
Lineage Acetabular Cup System (Ceramic)
Medicine Products: